At a glance
ClinicalIndex Comparison RecordPhase 3Active· 709 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Placebo for Various Advanced Cancer. Active but no longer recruiting, targeting 709 participants across 188 sites in 30 countries.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVarious Advanced Cancer
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Peru, Poland, Romania, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3Active
201620172018201920202021202220232024202520262027
First PostedDec 2015
Enrollment StartMar 2016
Primary CompletionJul 2020
TodayJul 2026
Study CompletionMay 2027
First PostedDec 16, 2015
Enrollment StartMar 22, 2016
Primary CompletionJul 17, 2020
Study CompletionMay 27, 2027
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 10.5 years ago
Interventions
Nivolumabbiological
Placeboother